SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Lowers Price Target to $33
SVB Leerink analyst Daina Graybosch maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Outperform and lowers the price target from $35 to $33.
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Innovent Biologics Inc (OTC:IVBIY) and Bolt Biotherapeutics Inc (NASDAQ:BOLT) have entered into a drug research and development collaboration…
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs
Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs)
Innovent
SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Raises Price Target to $35
SVB Leerink analyst Daina Graybosch maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Outperform and raises the price target from $34 to $35.
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)
Stocks That Hit 52-Week Lows On Thursday
During the morning session on Thursday, 152 stocks hit new 52-week lows.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)